12 August 2019
On July 30, 2019, FDA issued draft guidance that answers questions regarding priority review vouchers for certain rare pediatric disease treatments that meet criteria of the Food, Drug, & Cosmetic Act (FD&C Act). As part of the FD&C Act, FDA may give special incentives to companies for the development of treatments for rare pediatric diseases. This draft guidance revises a previous draft guidance and clarifies the qualifications and process for requesting priority review vouchers.
Specifically, the guidance gives detailed answers to questions regarding the definition of a rare pediatric disease, eligibility requirements, a sponsor’s responsibilities after approval of an application, designation information requests, the submission process, marketing applications, and use and transfer of a rare pediatric disease priority review voucher. The guidance also discusses drug-drug combinations, previously approved drugs, and orphan drug designation questions.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024